Welcome, Guest. Please login or register.
April 19, 2024, 12:20:47 pm

Login with username, password and session length


Members
  • Total Members: 37644
  • Latest: Aman08
Stats
  • Total Posts: 773211
  • Total Topics: 66337
  • Online Today: 581
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 3
Guests: 450
Total: 453

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: News  (Read 2780 times)

0 Members and 1 Guest are viewing this topic.

Offline Matland

  • Member
  • Posts: 74
News
« on: May 16, 2016, 11:24:42 am »
DOUBLE HIV BLOCK BY GENE TRANSFER
8 hours ago
Doherty Institute
SHARE THIS:     
A bold study to make cells resistant to HIV is now recruiting in Sydney. Researchers from the Kirby Institute have paired with the HIV biotech firm, Calimmune, to conduct a small human study of chemotherapy in conjunction with CAL-1.

CAL-1, otherwise known as LVsh5/C46, is basically an inactive virus that has two effects once it gets inside host cells. The first effect is to remove CCR5, the co-receptor found on the surface of white blood cells that helps HIV infect those cells. People who are naturally deficient in CCR5 are resistant to HIV infection. The second effect of CAL-1 is on HIV itself, by blocking some of the critical interactions between the virus and the cell it is trying to infect. The study will measure how well the CAL-1 treatment works, how long the treated cells can be detected in the body of trial participants and whether the treated cells have an effect on HIV levels when participants have a period off treatment.

For the study, participants have both bone-marrow stem cells and CD4+ T cells collected by leukapheresis after being given drugs that encourage bone marrow cells to move into the blood stream. The collected cells are then taken to a specialised laboratory where they are treated with CAL-1 and grown for a short period to increase their number. Participants are then administered a chemotherapy drug to prepare them for the re-infusion of the CAL-1 treated cells. The CAL-1 treated cells are then given as a one-off event and the participants monitored regularly for 6 months. Participants would then be taken off ART to see if the CAL-1 treated cells can control the infection on their own.

Online leatherman

  • Global Moderator
  • Member
  • Posts: 8,618
  • Google and HIV meds are Your Friends
Re: News
« Reply #1 on: May 16, 2016, 12:52:55 pm »
this post needs a better title

like "study recruiting in Sydney"
leatherman (aka Michael)

We were standing all alone
You were leaning in to speak to me
Acting like a mover shaker
Dancing to Madonna then you kissed me
And I think about it all the time
- Darren Hayes, "Chained to You"

Offline Matland

  • Member
  • Posts: 74
Re: News
« Reply #2 on: May 16, 2016, 01:39:36 pm »
this post needs a better title

like "study recruiting in Sydney"

Sorry my english is A bit poor :(

Offline Cosmicdancer

  • Member
  • Posts: 199
Re: News
« Reply #3 on: May 16, 2016, 08:35:18 pm »
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
2/2008 - 5/2015 - undetectable on Atripla
May, 2015 - UD, switched to Complera
September, 2015 - UD, 980 cd4, switched to Stribild (Complera interacted with acid reflux medication)
January, 2016 - Stribild, UD, 950 cd4
June, 2016 - UD, 929 cd4

Offline geobee

  • Member
  • Posts: 376
Re: News
« Reply #4 on: May 16, 2016, 11:32:22 pm »
I just got an email re: recruiting for this trial in San Francisco -- from Dr. Jay Lalezari, Quest Clinical Research:

Dear Quest Email Recipients,

Following on the successful cure of the "Berlin patient”, Quest research is conducting a study to see whether HIV can be eradicated following gene modification of a person’s own blood stem cells.

The general inclusion criteria include age < 70 years old, a T cell count less than 700, and an undetectable HIV viral load for past 6 months on stable ARV therapy.

Please note that 2 visits down to LA (at City of Hope Hospital-all expenses paid) will be required including a 1 month stay following receipt of the gene modified stem cells.

We are now open for screening and invite anyone who is interested to set up a time to meet with me in person and discuss in detail. Please email me or call Cooper at 415-353-0800 to schedule the appt.

Here’s hoping...
With Gratitude,

Dr Jay
Quest Research
415-353-0800

Offline Hoyland

  • Member
  • Posts: 99
Re: News
« Reply #5 on: May 17, 2016, 04:07:01 am »
Are you sure the invitation is for this Calimmune trial in Australia and not the UC Davis trial that is due to begin shortly?

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.